Atricure Inc ATRC Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$58.54 down $2.74, 4.47% at close Nov 6
Last close · Previous close $61.28
- Market cap
- At the Nov 6 close
- P/E ratio
- 195.13On last 12 months’ EPS
- Diluted EPS
- $0.30Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$58.54down $2.74, 4.47%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$61.28Nov 5
- Volume614.68KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume783.08KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $25.36 to $66.02; now $58.54
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
ATRC beat the S&P 500 in 4 of 7 periods.
| Period | ATRC and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ATRC: up 9.1% S&P 500: down 5.6% | ATRC beat the S&P 500 by 14.7 percentage points Beat |
| 3M | ATRC: up 48.2% S&P 500: down 4.1% | ATRC beat the S&P 500 by 52.3 percentage points Beat |
| YTD | ATRC: up 48.0% S&P 500: up 8.7% | ATRC beat the S&P 500 by 39.3 percentage points Beat |
| 1Y | ATRC: up 85.8% S&P 500: up 10.9% | ATRC beat the S&P 500 by 74.9 percentage points Beat |
| Long term | ||
| 3Y | ATRC: up 54.6% S&P 500: up 75.0% +15.6% vs +20.5% a year | ATRC trailed the S&P 500 by 20.4 percentage points Trailed |
| 5Y | ATRC: down 32.8% S&P 500: up 67.8% −7.6% vs +10.9% a year | ATRC trailed the S&P 500 by 100.6 percentage points Trailed |
| 10Y | ATRC: up 239.4% S&P 500: up 313.1% +13.0% vs +15.2% a year | ATRC trailed the S&P 500 by 73.7 percentage points Trailed |
$10,000 invested in ATRC 10 years ago (Nov 4, 2016) would be worth about $33,936 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
ATRC beat the S&P 500 in 4 of 7 periods.
| Period | ATRC and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ATRC: up 9.1% S&P 500: down 5.6% | ATRC beat the S&P 500 by 14.7 percentage points Beat |
| 3M | ATRC: up 48.2% S&P 500: down 4.3% | ATRC beat the S&P 500 by 52.5 percentage points Beat |
| YTD | ATRC: up 48.0% S&P 500: up 7.8% | ATRC beat the S&P 500 by 40.2 percentage points Beat |
| 1Y | ATRC: up 85.8% S&P 500: up 9.7% | ATRC beat the S&P 500 by 76.1 percentage points Beat |
| Long term | ||
| 3Y | ATRC: up 54.6% S&P 500: up 68.8% +15.6% vs +19.1% a year | ATRC trailed the S&P 500 by 14.2 percentage points Trailed |
| 5Y | ATRC: down 32.8% S&P 500: up 56.9% −7.6% vs +9.4% a year | ATRC trailed the S&P 500 by 89.7 percentage points Trailed |
| 10Y | ATRC: up 239.4% S&P 500: up 252.6% +13.0% vs +13.4% a year | ATRC trailed the S&P 500 by 13.2 percentage points Trailed |
$10,000 invested in ATRC 10 years ago (Nov 4, 2016) would be worth about $33,936 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$87.14
Closing high on . Now 32.8% below that record.
Split-adjusted daily closes since Aug 5, 2005.
Stock splits
ATRC hasn’t split since its price history begins in 2005.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Sep 30, 2026. “Last 12 months” means the four quarters from Oct 1, 2025 to Sep 30, 2026, and balance-sheet figures are as of Sep 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $589.80Mup 13.8%
- Net income
- $14.88M
- Diluted EPS
- $0.30
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Dec 31, 2024) | $124.28M | −$15.57M | −$0.33 |
| Q1 FY25 (Mar 31, 2025) | $123.62M | −$6.75M | −$0.14 |
| Q2 FY25 (Jun 30, 2025) | $136.14M | −$6.19M | −$0.13 |
| Q3 FY25 (Sep 30, 2025) | $134.27M | −$267.00K | −$0.01 |
| Q4 FY25 (Dec 31, 2025) | $140.50M | $1.76M | $0.04 |
| Q1 FY26 (Mar 31, 2026) | $141.25M | $108.00K | $0.00 |
| Q2 FY26 (Jun 30, 2026) | $153.60M | $8.96M | $0.18 |
| Q3 FY26 (Sep 30, 2026) | $154.45M | $4.06M | $0.08 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $274.33M | $50.20M | $1.09 |
| FY22 (Dec 31, 2022) | $330.38M | −$46.47M | −$1.02 |
| FY23 (Dec 31, 2023) | $399.25M | −$30.44M | −$0.66 |
| FY24 (Dec 31, 2024) | $465.31M | −$44.70M | −$0.95 |
| FY25 (Dec 31, 2025) | $534.53M | −$11.45M | −$0.24 |
Margins
- Gross 76.7%
- Operating 2.9%
- Net 2.5%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $52.94MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$68.55MLast 12 months
- Capital spending$15.61MLast 12 months
- 9.0%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $4.93MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$4.93MLast 12 months
9% of free cash flow
Balance sheet
- $187.03MAs of Sep 30, 2026
Cash plus short- and long-term marketable securities on the Sep 30, 2026 balance sheet.
- Total debt$93.11MAs of Sep 30, 2026
- Net cash$93.93MAs of Sep 30, 2026
- 4.33As of Sep 30, 2026
Current assets divided by current liabilities on the Sep 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.17As of Sep 30, 2026
Total debt divided by shareholders’ equity on the Sep 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 7 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✓Return on assets improved: passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- 2.9%Last 12 months
Over the last 12 months, Atricure’s net income was 2.9% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 2.2%Last 12 months
Over the last 12 months, Atricure’s net income was 2.2% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
About Atricure Inc
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Electrophysiologists, cardiothoracic and thoracic surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications, and post-operative pain management. AtriCure’s Isolator ® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent and long-standing persistent Afib. AtriCure’s AtriClip ® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE ® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Headquarters
- Ohio, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
ATRC news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
ATRC stock FAQ
What is ATRC stock’s price today?
Atricure (ATRC) traded at $58.54 at the close on , down $2.74 (4.47%) from the previous close of $61.28. Over the past 52 weeks it has traded between $25.36 and $66.02.
If you invested $1,000 in ATRC 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in ATRC on would be worth about $3,394 at the close on , a total return of +239.4%. The same $1,000 would be worth $672 if invested five years ago, $1,858 if invested one year ago, and $7,011 if invested 20 years ago. Past performance doesn’t predict future returns.
What is ATRC’s P/E ratio?
ATRC trades at 195.1 times its diluted earnings over the four quarters to ($0.30 per share), at the close. (How the P/E ratio works.)
How much revenue does Atricure make?
Atricure reported $589.8 million of revenue over the four quarters to , up 13.8% from the twelve months before. In its latest quarter (Q3 FY26, ended ) revenue was $154.5 million, up 15.0% from a year earlier.
Is Atricure profitable?
Yes. Atricure earned $14.9 million of net income over the four quarters to , a net margin of 2.5%, and its operating margin was 2.9% (what margins tell you).
What are ATRC’s earnings per share?
ATRC’s diluted earnings per share were $0.30 over the four quarters to , compared with −$0.61 in the twelve months before. The latest quarter (Q3 FY26) brought $0.08 per share, against −$0.01 a year earlier (how EPS works).
Does ATRC pay a dividend?
Atricure hasn’t paid a dividend in the last twelve months.
What is ATRC’s 52-week high and low?
Over the past 52 weeks ATRC has traded as low as $25.36 and as high as $66.02. At $58.54 at the close on , it is 11.3% below that high and 130.8% above the low.
What is ATRC’s all-time high?
ATRC’s highest closing price was $87.14 on , adjusted for stock splits. At $58.54 at the close on , it is 32.8% below that record.
Has ATRC stock ever split?
No. ATRC hasn’t split since its price history begins in 2005.
How has ATRC stock performed?
Including dividends and measured to the close on , ATRC has returned +48.0% so far this year and +85.8% over the past year, and −32.8% over five years (−7.6% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Atricure in?
Atricure is in the Healthcare sector and the Medical Instruments & Supplies industry, and is headquartered in Ohio, USA.
What exchange does ATRC trade on?
Atricure trades on the Nasdaq under the ticker symbol ATRC. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.